Redeye shares its initial comments on Modelon’s Q3 2024 figures, which were in line with our ARR exp...
Redeye provides an initial take following the release of Optomed’s Q3 2024 report.
Redeye comments on Truecaller’s Q3 2024 report and the new CEO appointment.
Q3 adj. EBIT of SEK 32m, +1% vs. ABGSC AUM flat q-o-q when adjusting for FX headwinds Q3 in line wit...
Redeye comments on the rights issue of SEK170m announced yesterday.
CapMan reported Q3 adjusted EBIT of EUR 2.0m, 23% below LSEG Data & Analytics consensus, most of whi...
Suominen's Q3 earnings fell significantly short of Vara Research consensus, mainly due to a EUR ~3m ...
Redeye comments on Medivir's Q3 report. We make changes to our base case as IGM Biosciences exits on...
Sales down 14% y-o-y as restaurant market headwinds intensify GC&MP strength improves mix, cost cont...
Redeyes view on the announced sizable order from a German operator.
Better than feared, sales still down 20% y-o-y, but margin held up well Near-term market and program...
Tessin tillhandahåller en digital investeringsplattform för säkerställda fastighetslån.
Administer's net sales declined by 3.9% y/y, reflecting the challenging market conditions that have ...
Marimekko's third quarter revenue was in line with our estimates, yet profitability fell a tad short...
Q3 in line, limited news on design wins Reiterates target of 4-6 design wins in 2024 Ambition of 50-...
Potentiell vändpunkt Adtraction minskade omsättningen med 17,5 procent i det tredje kvartalet.
Redeye continues to be positive to Bredband2 following a Q3 report that beat our estimates by delive...
Coor rapporterade ett kvartal under Analysguidens förväntan.
Spago Nanomedical’s Phase I/IIa study, Tumorad-01, is recruiting the next patient cohort on the two ...
EBITA -1% vs FactSet consensus, +27% y-o-y Strong order book of EUR 382m (+108% y-o-y) Neutral est c...
